Phase III results presented on amprenavir triple combination.
D019380:Anti-HIV Agents / Q000008:administration & dosage*; D002219:Carbamates; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage; D013449:Sulfonamides / Q000008:administration & dosage*; D015215:Zidovudine / Q000008:administration & dosage
D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; D019259:Lamivudine; D015215:Zidovudine; C095108:amprenavir